FTSE MIB
34.527,82 -297,19 (-0,85%) Dow Jones
39.806,77 -196,82 (-0,49%) Nasdaq
16.794,88 +108,91 (+0,65%) Nikkei 225
38.946,93 -122,75 (-0,31%) Petrolio
79,16 -0,64 (-0,80%) Bitcoin EUR
65.363,20 +3.743,02 (+6,07%)
aTyr Pharma, Inc. (LIFE)
Dopo ore:
| Chiusura precedente | 2,0000 |
| Aperto | 2,0200 |
| Denaro | 2,0500 x 300 |
| Lettera | 2,0800 x 400 |
| Min-Max giorno | 2,0000 - 2,0900 |
| Intervallo di 52 settimane | 1,0800 - 2,5500 |
| Volume | |
| Media Volume | 590.022 |
| Capitalizzazione | 142,853M |
| Beta (5 anni mensile) | 1,27 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,8800 |
| Prossima data utili | 07 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 22,60 |
GlobeNewswireaTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Jill Broadfoot, Chief Financial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place September 11 – 13, 2023, in New York, NY. Details of the presentation appear below: C
- GlobeNewswire
aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD expected to initiate in the third quarter of 2023. Ended the second quarter of 2023 with $112.0 million in cash, cash equivalents and investments. SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-
- GlobeNewswire
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic Sclerosis
Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to begin in the third quarter of 2023SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Commission (EC) granted orphan drug designation for the company’s lead therapeutic candidate, efzofitimod, for the treatment of
